Adult Dosing

Contraception

Balziva-28, Briellyn, Gildagia, Ovcon-35, Philith, Zenchent (ethinyl estradiol 0.035 mg/norethindrone 0.4 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by one inert tablet x 7 days
• After taking 28 tabs, start a new course the day after taking the last inert tablet

Brevicon 28-Day, Modicon 28, Necon 0.5/35, Wera (ethinyl estradiol 0.035 mg/norethindrone 0.5 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by one inert tablet x 7 days
• After taking 28 tabs, start a new course the day after taking the last inert tablet

Alyacen 1/35, Aranelle, Cyclafem 1/35, Dasetta 1/35, Necon 1/35, Norethin 1/35E-28, Ortho-Novum 1/35 (ethinyl estradiol 0.035 mg/norethindrone 1 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by one inert tablet x 7 days
• After taking 28 tabs, start a new course the day after taking the last inert tablet

Femcon Fe, Zenchent Fe, Zeosa (ethinyl estradiol 0.035 mg/norethindrone 0.4 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by one ferrous fumarate tablets x 7 days
• Start subsequent courses of tablets on the day after taking the last ferrous fumarate tablet

Generess Fe (ethinyl estradiol 0.025 mg/norethindrone 0.8 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 24 days, followed by one ferrous fumarate tablets x 4 days
• Start subsequent courses of tablets on the day after taking the last ferrous fumarate tablet

Gildess Fe 1.5/30, Junel Fe 1.5/30, Loestrin Fe 1.5/30, Microgestin Fe 1.5/30, Larin Fe 1.5/30 (ethinyl estradiol 0.03 mg/norethindrone 1.5 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by one ferrous fumarate tablets x 7 days
• Start subsequent courses of tablets on the day after taking the last ferrous fumarate tablet

Gildess Fe 1/20, Junel Fe 1/20, Loestrin Fe 1/20, Microgestin Fe 1/20, Larin Fe 1/20 (ethinyl estradiol 0.02 mg/norethindrone 1 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by one ferrous fumarate tablets x 7 days
• Start subsequent courses of tablets on the day after taking the last ferrous fumarate tablet

Junel 1.5/30, Loestrin 21 1.5/30, Microgestin 1.5/30 (ethinyl estradiol 0.03 mg/norethindrone 1.5 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by 7 days drug-free interval
• Start subsequent courses of tablets on the day after 7 days drug-free interval

Junel 1/20, Loestrin 21 1/20, Microgestin 1/20 (ethinyl estradiol 0.02 mg/norethindrone 1 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by 7 days drug-free interval
• Start subsequent courses of tablets on the day after 7 days drug-free interval

Lo Loestrin Fe (ethinyl estradiol 0.01 mg/norethindrone 1 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 24 days, followed by one inert tablet x 2 days, followed by one ferrous fumarate tablets x 2 days
• Start subsequent courses of tablets on the day after taking the last ferrous fumarate tablet

Loestrin 24 Fe (ethinyl estradiol 0.02 mg/norethindrone 1 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 24 days, followed by one ferrous fumarate tablets x 4 days
• Start subsequent courses of tablets on the day after taking the last ferrous fumarate tablet

Norethin 1/35E-21 (ethinyl estradiol 0.035 mg/norethindrone 1 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by 7 days drug-free interval
• Start subsequent courses of tablets on the day after 7 days drug-free interval

Nortrel 1/35, Norinyl 1+35 (ethinyl estradiol 0.035 mg/norethindrone 1 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or first Sunday after the onset of menses x 21 days, followed by one inert tablet x 7 days or 7 days drug-free interval
• Start subsequent courses of tablets on the day after taking the last inert tablet or the day after 7 days drug-free interval

Nortrel 0.5/35 (ethinyl estradiol 0.035 mg/norethindrone 0.5 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or first Sunday after the onset of menses x 21 days, followed by one inert tablet x 7 days
• Start subsequent courses of tablets on the day after taking the last inert tablet

Ovcon-50 (ethinyl estradiol 0.05 mg/norethindrone 1 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by one inert tablet x 7 days
• Start subsequent courses of tablets on the day after taking last inert tablet

Minastrin 24 Fe (ethinyl estradiol 0.02 mg/norethindrone 1 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 24 days, followed by one ferrous fumarate tablets x 4 days
• Start subsequent courses of tablets on the day after taking the last ferrous fumarate tablet

Note:

• Tablets should be taken at the same time each day. Tablets must be taken as recommended and at intervals not exceeding 24 hrs
• For the first cycle of Sunday-start regimen, use another nonhormonal back-up method of contraception until after the first 7 consecutive days of starting the tablet
• May be started 4 wks postpartum in women who elect not to breastfeed or >6 wks postpartum if breastfeeding
• The efficacy of Minastrin 24 Fe in women with a body mass index (BMI) > 35 kg/m² has not been evaluated

Pediatric Dosing

Contraception (postpubertal adolescents)

Balziva-28, Briellyn, Gildagia, Ovcon-35, Philith, Zenchent (ethinyl estradiol 0.035 mg/norethindrone 0.4 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by one inert tablet x 7 days
• After taking 28 tabs, start a new course the day after taking the last inert tablet

Brevicon 28-Day, Modicon 28, Necon 0.5/35, Wera (ethinyl estradiol 0.035 mg/norethindrone 0.5 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by one inert tablet x 7 days
• After taking 28 tabs, start a new course the day after taking the last inert tablet

Alyacen 1/35, Aranelle, Cyclafem 1/35, Dasetta 1/35, Necon 1/35, Norethin 1/35E-28, Ortho-Novum 1/35 (ethinyl estradiol 0.035 mg/norethindrone 1 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by one inert tablet x 7 days
• After taking 28 tabs, start a new course the day after taking the last inert tablet

Femcon Fe, Zenchent Fe, Zeosa (ethinyl estradiol 0.035 mg/norethindrone 0.4 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by one ferrous fumarate tablets x 7 days
• Start subsequent courses of tablets on the day after taking the last ferrous fumarate tablet

Generess Fe (ethinyl estradiol 0.025 mg/norethindrone 0.8 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 24 days, followed by one ferrous fumarate tablets x 4 days
• Start subsequent courses of tablets on the day after taking the last ferrous fumarate tablet

Gildess Fe 1.5/30, Junel Fe 1.5/30, Loestrin Fe 1.5/30, Microgestin Fe 1.5/30 (ethinyl estradiol 0.03 mg/norethindrone 1.5 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by one ferrous fumarate tablets x 7 days
• Start subsequent courses of tablets on the day after taking the last ferrous fumarate tablet

Gildess Fe 1/20, Junel Fe 1/20, Loestrin Fe 1/20, Microgestin Fe 1/20, Larin Fe 1/20 (ethinyl estradiol 0.02 mg/norethindrone 1 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by one ferrous fumarate tablets x 7 days
• Start subsequent courses of tablets on the day after taking the last ferrous fumarate tablet

Junel 1.5/30, Loestrin 21 1.5/30, Microgestin 1.5/30, Larin Fe 1.5/30 (ethinyl estradiol 0.03 mg/norethindrone 1.5 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by 7 days drug-free interval
• Start subsequent courses of tablets on the day after 7 days drug-free interval

Junel 1/20, Loestrin 21 1/20, Microgestin 1/20 (ethinyl estradiol 0.02 mg/norethindrone 1 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by 7 days drug-free interval
• Start subsequent courses of tablets on the day after 7 days drug-free interval

Lo Loestrin Fe (ethinyl estradiol 0.01 mg/norethindrone 1 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 24 days, followed by one inert tablet x 2 days, followed by one ferrous fumarate tablets x 2 days
• Start subsequent courses of tablets on the day after taking the last ferrous fumarate tablet

Loestrin 24 Fe (ethinyl estradiol 0.02 mg/norethindrone 1 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 24 days, followed by one ferrous fumarate tablets x 4 days
• Start subsequent courses of tablets on the day after taking the last ferrous fumarate tablet

Norethin 1/35E-21 (ethinyl estradiol 0.035 mg/norethindrone 1 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by 7 days drug-free interval
• Start subsequent courses of tablets on the day after 7 days drug-free interval

Nortrel 1/35, Norinyl 1+35 (ethinyl estradiol 0.035 mg/norethindrone 1 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or first Sunday after the onset of menses x 21 days, followed by one inert tablet x 7 days or 7 days drug-free interval
• Start subsequent courses of tablets on the day after taking the last inert tablet or the day after 7 days drug-free interval

Nortrel 0.5/35 (ethinyl estradiol 0.035 mg/norethindrone 0.5 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or first Sunday after the onset of menses x 21 days, followed by one inert tablet x 7 days
• Start subsequent courses of tablets on the day after taking the last inert tablet

Ovcon-50 (ethinyl estradiol 0.05 mg/norethindrone 1 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 21 days, followed by one inert tablet x 7 days
• Start subsequent courses of tablets on the day after taking last inert tablet

Contraception

Minastrin 24 Fe (ethinyl estradiol 0.02 mg/norethindrone 1 mg)

• 1 tab PO qd
• Start first active tablet on day 1 of menstrual cycle or 1st Sunday after onset of menses x 24 days, followed by one ferrous fumarate tablets x 4 days
• Start subsequent courses of tablets on the day after taking the last ferrous fumarate tablet

Note:

• Tablets should be taken at the same time each day. Tablets must be taken as recommended and at intervals not exceeding 24 hrs
• For the first cycle of Sunday-start regimen, use another nonhormonal back-up method of contraception until after the first 7 consecutive days of starting the tablet
• May be started 4 wks postpartum in women who elect not to breastfeed or >6 wks postpartum if breastfeeding
• The efficacy of Minastrin 24 Fe in women with a body mass index (BMI) > 35 kg/m² has not been evaluated

[Outline]

• Adult Dosing
• Pediatric Dosing

• Prevention of pregnancy

• Hypersensitivity to any of the ingredients of the product
• Thrombophlebitis or thromboembolic disorders
• History of deep vein thrombophlebitis or thromboembolic disorders
• Current or past history of cerebral vascular or coronary artery disease
• Valvular heart disease with complications
• Thrombogenic rhythm heart disorders
• Uncontrolled hypertension
• Hypertension with vascular disease
• Diabetes with vascular involvement
• Headaches with focal neurological symptoms
• Major surgery with prolonged immobilization
• Known or suspected carcinoma of the breast
• Known anaphylactic reaction or angioedema
• Carcinoma of the endometrium or other known or suspected estrogen- or progestin-dependent neoplasia
• Undiagnosed abnormal genital bleeding
• Cholestatic jaundice of pregnancy or jaundice with prior pill use
• Hepatic adenomas or carcinomas
• Acute or chronic hepatocellular disease with abnormal liver function
• Known or suspected pregnancy
• Smokers >35 yrs or heavy smokers
• Acquired or hereditary thrombophilias
• Antibody positive or unknown SLE
• Within 21 days postpartum or 6 wks postpartum if breastfeeding
• Known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders

• Women using oral contraceptives should be strongly advised not to smoke, as cigarette smoking increases the risk of serious cardiovascular side effects in these women. The risk further increases with age and with heavy smoking (15 cigarettes/day) and is quite marked in women over 35 years of age

Renal Dose Adjustment

• Renal impairment: Use with caution, dose adjustments not defined

Hepatic Dose Adjustment

• Active hepatic disease: Contraindicated

See Supplemental Patient Information

• Cigarette smokers are more prone to the risk of serious cardiovascular side effects from oral contraceptive use. Advise women who use contraceptives to avoid smoking [US Black Box Warning]
• Increased risk of several serious conditions such as MI, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease has been associated with the therapy. Risk of morbidity and mortality markedly increases in the presence of underlying risk factors such as hypertension, hyperlipidemias, obesity, and diabetes
• Oral contraceptives may potentiate the effects of well-known risk factors such as hypertension, diabetes, hyperlipidemias, age and obesity; these risk factors have been associated with an increased risk of heart disease. Use cautiously in women with cardiovascular disease risk factors
• Increased risk of thromboembolic and thrombotic disease has been reported with the use of OCP; risk of post-operative thromboembolic complications has been reported with the use of oral contraceptives. Discontinue use at least 4 weeks prior to and for 2 weeks after elective surgery of a type associated with an increase in risk of thromboembolism and during and following prolonged immobilization; initiate use not earlier than 4-6 weeks after delivery in women electing not to breastfeed
• Oral contraceptives may increase the risk of cerebrovascular events such as thrombotic and hemorrhagic strokes; this risk is greatest among older (>35 yrs) and hypertensive women who also smoke
• Decrease in serum HDL has been associated with an increased risk of ischemic heart disease. As progestational agents decrease serum HDL and estrogens increase HDL cholesterol, the net effect of an oral contraceptive depends on a balance achieved between doses of estrogen and progestogen and the nature and absolute amount of progestogen used in the contraceptives
• Individualize dosage in a way that it contains the least amount of estrogen and progestogen that is compatible with a low failure rate; new users should be started on preparations containing the lowest estrogen content producing satisfactory results
• Prolonged use of OCPs containing 50 mcg or higher estrogens may cause increased risk of vascular diseases
• Oral contraceptives may increase the risk of breast and cervical cancer. Discontinuation of OCP decreases this risk. Avoid use in females with known or suspected carcinoma of the breast or personal history of breast cancer
• Rarely, fatal benign hepatic adenomas have been reported with oral contraceptive use. Rupture of these benign, hepatic adenomas may cause intra-abdominal hemorrhage leading to death
• Oral contraceptives may cause retinal thrombosis leading to partial or complete loss of vision. Discontinue the drug if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions and initiate appropriate diagnostic and therapeutic measures
• Do not use oral contraceptives during pregnancy to treat threatened or habitual abortion
• Combination oral contraceptives may worsen existing gallbladder disease and may accelerate the development of this disease in previously asymptomatic women
• Estrogens at higher doses >75 mcg cause hyperinsulinism, while lower doses cause less glucose intolerance; progestogens increase insulin secretion and create insulin resistance. Hence, carefully monitor prediabetic and diabetic women while taking oral contraceptives
• Hypertension may occur during therapy. Closely monitor hypertensive women electing to use oral contraceptives; discontinue use in women with significant elevation of blood pressure
• Discontinue therapy on onset or exacerbation of migraine, development of headache with a new pattern that is recurrent, persistent or severe
• Bleeding irregularities such as breakthrough bleeding and spotting may occur, especially during the first 3 months of oral contraceptive use. Consider non-hormonal causes and initiate adequate diagnostic measures to rule out malignancy/pregnancy in the event of breakthrough bleeding or any abnormal vaginal bleeding
• Ectopic as well as intrauterine pregnancy may occur in contraceptive failures
• Counsel the patients that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases
• Consider physical examination and follow up in relevance to blood pressure, breasts, abdomen and pelvic organs, including cervical cytology, and perform relevant laboratory tests in all the women taking OCP
• Carefully monitor women with a strong family history of breast cancer or having breast nodules
• Closely monitor women who are being treated for hyperlipidemia. Consider nonhormonal contraception in women with uncontrolled dyslipidemia
• OCPs may cause some degree of fluid retention; use cautiously with careful monitoring in patients with conditions which might be aggravated by fluid retention
• Closely monitor women with a history of depression; discontinue use if depression recurs to a serious degree

Cautions: Use cautiously in

• Renal impairment
• Hepatic impairment
• Breastfeeding 6 wks-6 months postpartum
• Inflammatory bowel disease
• Diabetes mellitus
• Hypercholesterolemia
• Fluid retention
• History of depression
• Vomiting or diarrhea
• Obesity
• Hereditary angioedema

Supplemental Patient Information

• Inform patients that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases
• Instruct patients to take pill exactly as directed and at intervals not exceeding 24 hrs
• Advise women to use an additional method of protection until after the first 7 days of administration in the initial cycle
• Instruct women to start oral contraceptives no earlier than 4-6 weeks after delivery due to its association with an increased risk of thromboembolism. On termination of pregnancy, instruct patients to start oral contraceptives immediately or within 7 days after termination
• Advise patients to promptly report their physician on spotting or persisting breakthrough bleeding
• On missing one pill, instruct patients to take it as soon as they remember and then to take the next pill at the regular time
• Educate patients that missing a pill would cause spotting or light bleeding, and they may experience gastric irritation if they take the missed pill along with their regularly scheduled pill
• In case of a missed menstrual period, inform patients to consider the possibility of pregnancy, withholding oral contraceptives until pregnancy has been ruled out. Instruct patients to rule out pregnancy before continuing the contraceptive regimen even in patients who have adhered to the prescribed regimen but missed 2 consecutive periods

Pregnancy Category:X

Breastfeeding: Combination oral contraceptives probably do not affect the composition of milk substantially in healthy, well-nourished mothers and do not adversely affect long-term infant growth and development, but can transiently affect growth negatively during the first month after introduction. Rarely, reversible breast enlargement has been reported with higher doses of estrogen. Ethinyl estradiol in doses of 30 mcg daily or greater can suppress lactation leading to earlier discontinuation of breastfeeding than nonhormonal or progestin-only contraception. The magnitude of the effect on lactation likely depends on the dose and the time of introduction postpartum. As per US expert opinion, the risks of combination contraceptive products usually outweigh the benefits before 4 weeks postpartum. Between 4 weeks and 6 months postpartum, the advantages of using the method generally outweigh the theoretical or proven risks. After 6 months postpartum, combination contraceptives can be used, but progestin-only methods are preferred if breastfeeding will be continued. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 24 June 2011).Small amounts of oral contraceptive steroids are excreted in breastmilk of nursing mothers and a few adverse effects on the child have occurred, including jaundice and breast enlargement. Combination oral contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk. Manufacturer advises the nursing mother to avoid using combination oral contraceptives and to use other forms of contraception until she has completely weaned her child.

• CV: Thromboembolism, thrombosis, thrombophlebitis, MI, TIA, coronary thrombosis, pulmonary embolism, arterial thromboembolism, edema, hypertension, thromboembolic phenomena, aggravation of varicose veins
• GI: Colitis, abdominal cramps, bloating, gallbladder disease, mesentric thrombosis, pancreatitis, nausea, vomiting
• HEPA: Budd-Chiari syndrome, hepatic adenomas, hepatic carcinomas, benign liver tumors, cholestatic jaundice
• GU: Cystitis-like syndrome, impaired renal function, hemolytic uremic syndrome, fluid retention
• EENT: Contact lens intolerance, ocular lesions, optic neuritis, retinal thrombosis, cataracts, changes in corneal curvature
• CNS: Migraine headache, stroke, dizziness, nervousness, chorea exacerbation, cerebral hemorrhage, cerebral thrombosis
• PSYCHIATRIC: Emotional lability, depression
• METABOLIC: Weight changes, appetite changes, glucose intolerance, decreased serum folate levels, carbohydrate intolerance, increased cholesterol
• DERM: Erythema multiforme, erythema nodosum, rash, acne, chloasma, loss of scalp hair, hirsutism, melasma, hemorrhagic eruption
• IMMU: Porphyria exacerbation, SLE exacerbation
• REPRODUCTIVE: Amenorrhea, altered menstrual flow, breakthrough bleeding, pre-menstrual syndrome, dysmenorrhea, spotting, changes in cervical erosion and secretion, vaginal candidiasis, vaginitis, decreased lactation, changes in libido, breast tenderness, breast enlargement, breast secretion, temporary infertility after treatment discontinuation
• HYPERSENSITIVITY: Anaphylaxis/anaphylactoid reactions

Ethinyl estradiol

• Estrogens; increase the hepatic synthesis of sex hormone binding globulin, thyroid-binding globulin, and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, thereby reducing the secretion of gonadotropin-releasing hormone (GnRH). Also, inhibits ovulation and alters cervical mucus and endometrium, which prevents penetration of sperm into the uterus and implantation of the egg
• Metabolized in the liver and GI tract; CYP450: 3A4 substrate
• Excreted in urine, bile, and feces
• Half-life: 17.1+/-4.4 hrs (mean 9 hours)

Norethindrone

• Contraceptive agent; acts by suppression of pituitary gonadotropins, inhibits ovulation, and induces changes in the cervical mucus thereby increasing the difficulty of sperm entry into the uterine cavity and the endometrium, reducing likelihood of implantation
• Metabolized by liver; CYP450: 3A4 substrate
• Excretion: Urine 50%; feces 20-40%; <5% unchanged
• Half-life: 8.6+/-3.7 hrs (mean 17 hours)

US Trade Name(s)

• Alyacen 1/35
• Aranelle
• Balziva-28
• Brevicon 28-Day
• Briellyn
• Cyclafem 1/35
• Dasetta 1/35
• Femcon Fe
• Generess Fe
• Gildagia
• Gildess Fe 1.5/30
• Gildess Fe 1/20
• Junel 1.5/30
• Junel 1/20
• Junel Fe 1.5/30
• Junel Fe 1/20
• Lo Loestrin Fe
• Loestrin 1.5/30
• Loestrin 1/20
• Loestrin 24 Fe
• Loestrin Fe 1.5/30
• Loestrin Fe 1/20
• Microgestin 1.5/30
• Microgestin 1/20
• Microgestin Fe 1.5/30
• Microgestin Fe 1/20
• Modicon 28
• Necon 0.5/35
• Necon 1/35
• Norethin 1/35E-21
• Norethin 1/35E-28
• Norinyl 1+35
• Nortrel 0.5/35
• Nortrel 1/35
• Ortho-Novum 1/35
• Ovcon-35
• Ovcon-50
• Philith
• Wera
• Zenchent
• Zenchent Fe
• Zeosa
• Femhrt
• Pirmella 1/35
• Minastrin 24 Fe
• Larin Fe 1.5/30
• Larin Fe 1/20
• Larin 1/20
• Vyfemla
• Lo Minastrin Fe
• Larin 1.5/30

US Availability

ethinyl estradiol/norethindrone (generic)

• TABS: 0.035 mg/0.4 mg (21 tabs), 7 inert tabs
• TABS: 0.035 mg/0.4 mg (21 tabs)
• TABS: 0.035 mg/0.5 mg (21 tabs), 7 inert tabs
• TABS: 0.035 mg/1 mg (21 tabs)
• TABS: 0.035 mg/1 mg (21 tabs), 7 inert tabs
• TABS: 0.035 mg/0.75 mg
• TABS: 0.05 mg/1 mg (21 tabs), 7 inert tabs
• TABS: 0.02 mg/1 mg (21 tabs)
• TABS: 0.02 mg/1 mg (21 tabs), 75 mg ferrous fumarate (7 tabs)
• CHEW TABS : 0.025 mg/0.8 mg (24 tabs), 75 mg ferrous fumarate (4 tabs)

Balziva-28, Briellyn, Gildagia, Ovcon-35, Philith, Zenchent (ethinyl estradiol/norethindrone)

• TABS: 0.035 mg/0.4 mg (21 tabs), 7 inert tabs

Brevicon 28-Day, Modicon 28, Necon 0.5/35, Wera (ethinyl estradiol/norethindrone)

• TABS: 0.035 mg/0.5 mg (21 tabs), 7 inert tabs

Alyacen 1/35, Aranelle, Cyclafem 1/35, Dasetta 1/35, Necon 1/35, Norethin 1/35E-28, Ortho-Novum 1/35 (ethinyl estradiol/norethindrone)

• TABS: 0.035 mg/1 mg (21 tabs), 7 inert tabs

Zenchent Fe, Zeosa (ethinyl estradiol/norethindrone)

• TABS : 0.035 mg/0.4 mg (21 tabs), 75 mg ferrous fumarate (7 tabs)

Generess Fe (ethinyl estradiol/norethindrone)

• TABS : 0.025 mg/0.8 mg (24 tabs), 75 mg ferrous fumarate (4 tabs)

Gildess Fe 1.5/30, Junel Fe 1.5/30, Loestrin Fe 1.5/30, Microgestin Fe 1.5/30, Larin Fe 1.5/30 (ethinyl estradiol/norethindrone)

• TABS : 0.03 mg/1.5 mg (21 tabs), 75 mg ferrous fumarate (7 tabs)

Gildess Fe 1/20, Junel Fe 1/20, Loestrin Fe 1/20, Microgestin Fe 1/20, Larin Fe 1/20 (ethinyl estradiol/norethindrone)

• TABS : 0.02 mg/1 mg (21 tabs), 75 mg ferrous fumarate (7 tabs)

Junel 1.5/30, Loestrin 21 1.5/30, Microgestin 1.5/30 (ethinyl estradiol/norethindrone)

• TABS: 0.03 mg/1.5 mg (21 tabs)

Junel 1/20, Loestrin 21 1/20, Microgestin 1/20, Larin 1/20 (ethinyl estradiol/norethindrone)

• TABS: 0.02 mg/1 mg (21 tabs)

Lo Loestrin Fe, Lo Minastrin Fe (ethinyl estradiol/norethindrone)

• TABS: 0.01 mg/1 mg (24 tabs), 2 inert tabs, 75 mg ferrous fumarate (2 tabs)

Loestrin 24 Fe (ethinyl estradiol/norethindrone)

• TABS : 0.02 mg/1 mg (24 tabs), 75 mg ferrous fumarate (4 tabs)

Norethin 1/35E-21 (ethinyl estradiol/norethindrone)

• TABS: 0.035 mg/1 mg (21 tabs)

Nortrel 1/35, Norinyl 1+35 (ethinyl estradiol/norethindrone)

• TABS: 0.035 mg/1 mg (21 tabs), 7 inert tabs
• TABS: 0.035 mg/1 mg (21 tabs)

Nortrel 0.5/35 (ethinyl estradiol/norethindrone)

• TABS: 0.035 mg/0.5 mg (21 tabs), 7 inert tabs

Ovcon-50

• TABS: 0.05 mg/1 mg (21 tabs), 7 inert tabs

Femcon Fe

• CHEW TABS : 0.035 mg/0.4 mg (21 tabs), 75 mg ferrous fumarate (7 tabs)

Minastrin 24 Fe (ethinyl estradiol/norethindrone)

• CHEW TABS: 0.02 mg/1 mg (24 tabs), 75 mg ferrous fumarate (4 tabs)

Femhrt (ethinyl estradiol/norethindrone)

• TABS: 0.0025 mg/0.5 mg (21 tabs), 7 inert tabs

Vyfemla (ethinyl estradiol/norethindrone)

• TABS: 0.035 mg/0.4 mg (21 tabs), 7 inert tabs

Larin 1.5/30 (ethinyl estradiol/norethindrone)

• TABS: 0.03 mg/1.5 (21 tabs)

Canadian Trade Name(s)

• Brevicon 0.5/35
• Brevicon 1/35
• Ortho 1/35
• Ortho 0.5/35
• Select 1/35

Canadian Availability

Brevicon 0.5/35, Ortho 0.5/35 (ethinyl estradiol/norethindrone)

• TABS: 0.035 mg/0.5 mg (21 tabs)
• TABS: 0.035 mg/0.5 mg (21 tabs), 7 inert tabs

Brevicon 1/35, Ortho 1/35, Select 1/35 (ethinyl estradiol/norethindrone)

• TABS: 0.035 mg/1 mg (21 tabs)
• TABS: 0.035 mg/1 mg (21 tabs), 7 inert tabs

UK Trade Name(s)

• Brevinor
• Norimin
• Ovysmen

UK Availability

Brevinor, Ovysmen (ethinyl estradiol/norethisterone)

• TABS: 0.035 mg/0.5 mg (21 tabs)

Norimin (ethinylestradiol/norethisterone)

• TABS: 0.035 mg/1 mg (21 tabs)

Australian Trade Name(s)

• Brevinor 21 Day
• Brevinor 28 Day
• Brevinor-1 21
• Brevinor-1 28

Australian Availability

Brevinor 21 Day (ethinyloestradiol/norethisterone)

• TABS: 0.035 mg/0.5 mg (21 tabs)

Brevinor 28 Day (ethinyloestradiol/norethisterone)

• TABS: 0.035 mg/0.5 mg (21 tabs), 7 inert tabs

Brevinor-1 21 (ethinyloestradiol/norethisterone)

• TABS: 0.035 mg/1 mg (21 tabs)

Brevinor-1 28 (ethinyloestradiol/norethisterone)

• TABS: 0.035 mg/1 mg (21 tabs), 7 inert tabs

[Outline]

Obstetrics/Gynecology

Contraceptives

Estrogen And Progestin Combination

Pricing data from www.DrugStore.com in U.S.A.

• Ortho-Novum 1/35 (28) 1-35 MG-MCG TABS [Disp Pack] (JANSSEN)
  28 mg-mcg = $57.99
  84 mg-mcg = $152.98
• Loestrin Fe 1/20 1-20 MG-MCG TABS [Disp Pack] (TEVA/WOMENS HEALTH)
  28 mg-mcg = $93.99
  84 mg-mcg = $260.97
• Lo Loestrin Fe 1 MG-10 MCG / 10 MCG TABS [Disp Pack] (WARNER CHILCOTT PROF PROD DIV)
  28 10 mcg = $80.99
  84 10 mcg = $222.97
• Loestrin Fe 1.5/30 1.5-30 MG-MCG TABS [Disp Pack] (TEVA/WOMENS HEALTH)
  28 mg-mcg = $95.99
  84 mg-mcg = $264.98
• Loestrin 24 Fe 1-20 MG-MCG TABS [Disp Pack] (WARNER CHILCOTT PROF PROD DIV)
  28 mg-mcg = $80.99
  84 mg-mcg = $219.98
• Microgestin FE 1.5/30 1.5-30 MG-MCG TABS [Disp Pack] (WATSON LABS)
  28 mg-mcg = $29.99
  56 mg-mcg = $49.97
• Zeosa 0.4-35 MG-MCG CHEW [Disp Pack] (TEVA PHARMACEUTICALS USA)
  28 mg-mcg = $72.99
  84 mg-mcg = $199.98
• Junel 1.5/30 1.5-30 MG-MCG TABS [Disp Pack] (TEVA PHARMACEUTICALS USA)
  21 mg-mcg = $29.99
  63 mg-mcg = $79.97
• Junel FE 1.5/30 1.5-30 MG-MCG TABS [Disp Pack] (TEVA PHARMACEUTICALS USA)
  28 mg-mcg = $29.99
  56 mg-mcg = $47.97
• Femcon Fe 0.4-35 MG-MCG CHEW [Disp Pack] (WARNER CHILCOTT PROF PROD DIV)
  28 mg-mcg = $85.99
  84 mg-mcg = $249.97
• Ovcon-50 50-1 MCG-MG TABS [Disp Pack] (WARNER CHILCOTT PROF PROD DIV)
  28 mcg-mg = $97.99
  84 mcg-mg = $267.96
• Zenchent 0.4-35 MG-MCG TABS [Disp Pack] (WATSON LABS)
  28 mg-mcg = $43.99
  84 mg-mcg = $125.97
• Junel 1/20 1-20 MG-MCG TABS [Disp Pack] (TEVA PHARMACEUTICALS USA)
  21 mg-mcg = $27.99
  63 mg-mcg = $75.97
• Zenchent FE 0.4-35 MG-MCG CHEW [Disp Pack] (WATSON LABS)
  28 mg-mcg = $72.99
  84 mg-mcg = $195.96
• Junel FE 1/20 1-20 MG-MCG TABS [Disp Pack] (TEVA PHARMACEUTICALS USA)
  28 mg-mcg = $28.99
  84 mg-mcg = $69.97

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.

Drug Name: Femcon FE 28 Day Pack

Ingredient(s): Ethinyl Estradiol mixture with Ferrous fumarate and Norethindrone

Imprint: PD;622

Color(s): Brown

Shape: Round

Size (mm): 6.00

Score: 1

Inactive Ingredient(s): ferrous fumarate / cellulose, microcrystalline / magnesium stearate / povidone / sodium starch glycolate type a potato

Drug Label Author:
Warner Chilcott (US), LLC

DEA Schedule:
Non-Scheduled

Drug Name: Zenchent 28 Day Pack

Ingredient(s): Ethinyl Estradiol mixture with Inert Ingredients and Norethindrone

Imprint: WC;781

Color(s): White

Shape: Capsule

Size (mm): 7.00

Score: 1

Inactive Ingredient(s): lactose monohydrate / magnesium stearate / starch, corn

Drug Label Author:
Watson Pharma, Inc.

DEA Schedule:
Non-Scheduled